scholarly journals Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2017
Author(s):  
Maitane González-Arceo ◽  
Saioa Gómez-Zorita ◽  
Leixuri Aguirre ◽  
María P. Portillo
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Scientific Evidence ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Positive Effects ◽  
Wide Range ◽  
Preventive Effects ◽  
Alcoholic Fatty Liver Disease

The present review aims to gather scientific evidence regarding the beneficial effects of microalgae and macroalgae extracts on non-alcoholic fatty liver disease (NAFLD). The described data show that both microalgae and macroalgae improved this alteration. The majority of the reported studies analysed the preventive effects because algae were administered to animals concurrent with the diet that induced NAFLD. The positive effects were demonstrated using a wide range of doses, from 7.5 to 300 mg/kg body weight/day or from 1 to 10% in the diet, and experimental periods ranged from 3 to 16 weeks. Two important limitations on the scientific knowledge available to date are that very few studies have researched the mechanisms of action underlying the preventive effects of microalgae on NAFLD and that, for the majority of the algae studied, a single paper has been reported. For these reasons, it is not possible to establish the best conditions in order to know the beneficial effects that these algae could bring. In this scenario, further studies are needed. Moreover, the beneficial effects of algae observed in rodent need to be confirmed in humans before we can start considering these products as new tools in the fight against fatty liver disease.

scholarly journals Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease

2018 ◽  
Vol 37 (1) ◽  
pp. 63-68 ◽  
Author(s):  
Roger F. Butterworth ◽  
Ali Canbay
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Preliminary Report ◽  
Liver Enzymes ◽  
Hepatic Microcirculation ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Anti Oxidant ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited. Summary: L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6–9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with non-alcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties. Key Messages: (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA’s ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.

scholarly journals Hepatoprotective properties of glycyrrhizic acid

2020 ◽  
pp. 96-108
Author(s):  
S. V. Okovity ◽  
K. L. Raikhelson ◽  
A. V. Volnukhin ◽  
D. A. Kudlai
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intrahepatic Cholestasis ◽  
Fatty Liver Disease ◽  
Glycyrrhizic Acid ◽  
Evidence Base ◽  
Alcoholic Fatty Liver ◽  
Organ Systems ◽  
Wide Range ◽  
Alcoholic Fatty Liver Disease

The review is devoted to the problem of treatment of non-alcoholic fatty liver disease, which is the most common pathology of the hepato-biliary system worldwide and is characterized by an increasing frequency, including of more severe forms. A wide range of pathogenetic relationships of non-alcoholic fatty liver disease with diseases of other organ systems, primarily with diseases of the cardiovascular system, type 2 diabetes mellitus, chronic kidney disease and diseases of the biliary tract, is presented. The main mechanisms of comorbidity are insulin resistance, oxidative stress, inflammation, disorders of carbohydrate and fat metabolism. An approach to the therapy of this disease based on the concept of comorbidity has been substantiated. As a rational therapeutic choice, a molecule of glycyrrhizic acid is presented, which has pleiotropic effects, including anti-inflammatory, antioxidant, antifibrotic and immunomodulatory effects. The evidence base for glycyrrhizic acid is formed by a large array of clinical trials, including randomized placebo-controlled trials conducted both in Russia and abroad, in infectious and non-infectious liver diseases, including non-alcoholic fatty liver disease. Attention is focused on non-alcoholic fatty liver disease with intrahepatic cholestasis associated with a more severe course and high rates of disease progression. A theoretical justification for the use of a combination of glycyrrhizic acid and ursodeoxycholic acid in such patients is presented. The reason for this is the potential synergy of the two molecules, based on the induction of CYP3A4, and associated with the effect on inflammation, as a factor in the development of intrahepatic cholestasis and cholestasis itself.

scholarly journals Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies

2021 ◽  
Vol 10 (17) ◽  
pp. 3783
Author(s):  
Julie Steen Pedersen ◽  
Marte Opseth Rygg ◽  
Reza Rafiolsadat Serizawa ◽  
Viggo Bjerregaard Kristiansen ◽  
Nicolai J. Wewer Albrechtsen ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Plasma Lipid ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease

Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histological assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Consequently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p < 0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.

scholarly journals Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease

2019 ◽  
Vol 12 (5) ◽  
pp. dmm039206 ◽  
Author(s):  
Sara Carbajo-Pescador ◽  
David Porras ◽  
María Victoria García-Mediavilla ◽  
Susana Martínez-Flórez ◽  
María Juarez-Fernández ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
In Vivo Model ◽  
Alcoholic Fatty Liver ◽  
Barrier Integrity ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease

The Beneficial Effects of Silymarin in Treatment of Experimentally Induced Non-Alcoholic Fatty Liver Disease in Rats

2018 ◽  
Vol 86 (3) ◽  
pp. 1055-1064
Author(s):  
HEBAT ALLAH M. MAHMOUD, M.Sc.; FATMA A. MAHMOUD, M.D. ◽  
GHADA HASHEM, M.D.; HANAN H. AHMED, M.D. ◽  
HESHAM M. MAHMOUD, M.D.
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease ◽  
Experimentally Induced
Sign in / Sign up

Export Citation Format

Share Document